Cannabidiol (CBD) in Pain Reduction for Knee Osteoarthritis

Exclusion Criteria

• •Knee Injections within the last 3 months (cortisone, PRP, hyaluronic acid)
• •Legally incompetent or mentally impaired (e.g., minors, Alzheimer's subjects, dementia, etc.)
• •Younger than 40 years of age
• •Older than 75 years of age
• •Any patient considered a vulnerable subject: pregnant women or fetuses, children, cognitively impaired adults, prisoners
• •History of cannabis abuse or dependence
• •History of coagulation abnormalities and thromboembolic disease or current abnormal coagulation test values
• •History of stroke or acute coronary syndromes within 3 months
• •Abnormal coagulation profile
• •Renal failure (serum creatinine \> 250 μmol/L \[2.83 mg/dL\]) or liver cirrhosis
• •Patients that have been on opioid management for any reason just prior to the study
• •Patients with known inflammatory arthritis (such as rheumatoid arthritis, gout, pseudogout etc)
• •Patients with a large effusion
• •Patients with a BMI \> 35
• •Patients meeting the DSM-V for major psychiatric illness, such as bipolar disorder
• •Patients diagnosed with major depression, psychosis, or substance abuse disorder
• •Patients with current or a history of suicidal ideation
• •Breastfeeding females
• •Abnormal LFTs
• •Patients with major neurological disorders, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, history of traumatic brain/head injury, or seizures
• •Patients with moderate (Child-Pugh B) and severe hepatic impairment (Child-Pugh C).
• •Patients taking moderate or strong inhibitors of CYP3A4 and CYP2C19 (listed below) concomitantly will be considered for exclusion if determined to be clinically significant by the treating physicians
• •Patients taking strong CYP3A4 and CYP2C19 inducers (listed below) concomitantly will be considered for exclusion if determined to be clinically significant by the treating physicians
• •Patients taking substrates of UTG1A9, UTGB17, CYP2A1, CYP2B6, CYP2C8, CYP2C9 and CYP2C19 (listed below) concomitantly will be considered for exclusion if determined to be clinically significant by the treating physicians